



The Michael J. Fox Foundation for Parkinson's Research & The New York Academy of Sciences
2011 Parkinson's Disease Therapeutics Conference
New York, NY
October 26, 2011

Oct 26, 2010	
8.30	Breakfast
9.00 – 9.20	Welcome by Todd Sherer, PhD and David Weiner, MD
9:20 – 11:00	<p>Novel Therapeutic Targets</p> <p><i>P. Jeffrey Conn, PhD, Vanderbilt University</i> "Discovery of mGluR4 Potentiators for Symptomatic and Disease-Modifying Treatment of PD"</p> <p><i>Paola P. Piccini, MD, PhD, FRCP, Imperial College London</i> "The Role of Striatal Serotonergic Terminals in L-dopa Induced-Dyskinesia in PD Patients: An <i>In vivo</i> PET Study"</p> <p><i>Andres Björklund, MD, PhD, Lund University</i> "NURR1 as a Target for Parkinson's Disease"</p> <p><i>D. James Surmeier, PhD, Northwestern University</i> "Small Molecule Inhibitors of CAV 123 Calcium Channels as Neuroprotective PD Therapies"</p>
11:00 – 11:15	Networking Break/Poster Viewing
11:15 – 12:30	<p>Novel Therapeutic Targets (cont'd)</p> <p><i>Nic Dzamko, PhD, University of Dundee</i> "Exploiting Ser910/935 Phosphorylation and 14-3-3 Binding to Develop Biomarkers for LRRK2 Activity"</p> <p><i>Markus Mandler, PhD, AFFiRIS AG</i> "AFFITOPE Based Immunotherapeutic Strategies for Parkinson's Disease"</p> <p><i>Ronald B. Tjalkens, PhD, Colorado State University</i> "Targeting Glia in PD with Novel Anti-inflammatory Therapeutics"</p>
12:30 – 1:30	Lunch/Poster Viewing
1:30 – 3:00	<p>Research Tools and Resources</p> <p><i>Patrizia Fanara, PhD, KineMed Inc.</i> "Cerebrospinal Fluid Biomarkers of Microtubule-mediated Axonal Transport for Monitoring of Disease Progression and Therapeutic Interventions in Parkinson's Disease"</p>

	<p><i>Ole Isacson, Dr.Med.Sci, Harvard University</i> “Patient-specific iPS Cell-derived Neurons and Disease-associated LRRK2 Mutations for Parkinson's Disease Research”</p> <p><i>Ken Marek, MD, The Institute for Neurodegenerative Disorders and Leslie Shaw, PhD, The University of Pennsylvania</i> “Cross-comparison of Alpha-Synuclein Assays and Update on the Parkinson’s Progression Markers Initiative”</p>
3:00 – 3:30	Networking Break/Poster Viewing
3:30 – 4:30	<p>Hot Topics in Parkinson’s Disease Research</p> <p><i>John Q. Trojanowski, MD, PhD, University of Pennsylvania</i> “Toxic Forms of Alpha-Synuclein”</p> <p><i>Darryle D. Schoepp, PhD, Merck and Company, Inc.</i> “Thoughts on PD Drug Development: Challenges and Opportunities”</p>
4:30 – 5:00	Closing Remarks
5:00 – 7:00	Cocktail Reception/Poster Viewing